Poniard Pharmaceuticals, Inc. (PARD.O)
2.30USD
8 Dec 2009
$-0.04 (-1.71%)
$2.30
--
$2.38
$2.26
1,311,086
2,678,552
$9.14
$1.05
PARD.O
About
Overall
| Beta: | 1.20 |
| Market Cap (Mil.): | $80.41 |
| Shares Outstanding (Mil.): | 34.96 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| PARD.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 12.58 | 4.63 |
| EPS (TTM): | -5.06 | -- | -- |
| ROI: | -83.67 | 1.90 | 2.80 |
| ROE: | -117.21 | 3.14 | 4.09 |
UPDATE 1-Poniard shares up on positive colorectal cancer data
* Shares up as much as 36 pct Nov 17 (Reuters) - Poniard Pharmaceuticals Inc said its lead drug picoplatin continued to show comparable efficacy to an already approved treatment in a mid-stage colorectal cancer study, sending its shares up as much as 36 percent.
UPDATE 2-Poniard shares tank after cancer drug misses study goal
* Shares close down 75 pct (Recasts; adds background, analysts' comments, updates shares movement)
International Biotech waiting for market to retrace
LONDON (Reuters) - Small-cap biotechnology shares have become too expensive and are poised for a fall, said David Pinniger, a investment manager at International Biotechnology Trust.
FUNDVIEW-Int'l Biotech waiting for market to retrace
LONDON, Oct 15 (Reuters) - Small-cap biotechnology shares have become too expensive and are poised for a fall, said David Pinniger, a investment manager at International Biotechnology Trust .
After Medarex buy, biotech investors ask who's next
NEW YORK (Reuters) - Investors bid up shares of Regeneron Pharmaceuticals Inc and Seattle Genetics Inc on Thursday after Medarex Inc agreed to be acquired by Bristol-Myers Squibb Co at a 90 percent premium.
After Medarex buy, biotech investors ask who's next
NEW YORK (Reuters) - Investors bid up shares of Regeneron Pharmaceuticals Inc and Seattle Genetics Inc on Thursday after Medarex Inc agreed to be acquired by Bristol-Myers Squibb Co at a 90 percent premium.
UPDATE 1-After Medarex buy, biotech investors ask who's next
* Regeneron, Seattle Genetics potential targets - analyst
HEADLINE STOCKS-U.S. stocks on the move on May 28
(Updates to afternoon trading, adds Lions Gate, Perry Ellis, Revlon, Devon Energy, Sanderson and Express Scripts)
UPDATE 1-Poniard says cancer drug shows favorable results
* Picoplatin suggests lower colon-cancer nerve-damage risk
HEADLINE STOCKS-U.S. stocks on the move on May 28
(Updates to after the open, adds GM, Ford, Target, FreeSeas and Blue Coat)
Competitors
| Price | Change | |
|---|---|---|
| Abbott Laboratories (ABT.N) | $53.24 | -0.42 |
| Amgen, Inc. (AMGN.OQ) | $55.93 | -0.55 |
| AstraZeneca plc (AZN.L) | £2,797.00 | -5.50 |
| Baxter International Inc. (BAX.N) | $55.12 | -0.89 |
| Bristol Myers Squibb Co. (BMY.N) | $24.90 | -0.38 |
| Bristol Myers Squibb Co. (BMY_p.N) | $440.00 | 0.00 |
| Celgene Corporation (CELG.OQ) | $54.32 | -1.21 |
| Dainippon Sumitomo Pharma Co., Ltd. (4506.T) | ¥926.00 | -3.00 |
| Eli Lilly & Co. (LLY.N) | $36.51 | -0.56 |
| Genentech, Inc. (DNA.N) | -- | -- |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
